tbuckley/cabot-search huggingface dataset:
Immunological recovery in children with ALL at the end of intensive therapy, at the completion of therapy, and up to one year off therapy. A follow-up study
Authors: S. P. Kosmidis, M. Baka, D. Bouhoutsou, C. Kallergi, D. Doganis, N. Douladiris, M. Varvoutsi, A. Pourtsidis, A. Sotiropoulou, P. S. Papageirgiou, H. V. Kosmidis
Journal: Journal of Clinical Oncology (2006)

9031 Background: Children undergoing therapy for ALL are known to have impaired immune function. (ASCO 2005, abstract #8541). Methods: We prospectively evaluated the humoral and cellular immunity in children with ALL at the end of intensive therapy (Evaluation 1 -E1) and values were compared to those at the completion of therapy (E2), at 6 months (E3) and at 12 months thereafter (E4). Investigations among others included CBC, lymphocyte subpopulation by flow cytometry (CD3, CD4, CD8, CD16, CD19, CD3 DR, CD45RO and CD45RA), immunoglobulin levels by nephelometry, antibody titers to MMR immunization and skin tests to Candida, Trichophyton, diphtheria toxin and tetanus toxoid. Seventy three children with ALL, 48 boys, 25 girls (median age 4 years on diagnosis) treated according to BFM 95 protocol were evaluated. Of the 139 evaluations, 41 were E1, 43 E2, 37 E3, 18 E4 and data were analyzed with a non parametric Mann Whitney test. Results: Immunoglobulin levels at E1 were low in the majority of children and were increasing at E2 and E3 and E4 for IgA and IgM (median values of parameters studied are shown in the table in mg/dl for immunoglobulins and % for CD’s). Of the 70 children immunized with MMR only 11 had absent IgG antibodies. Also, skin tests were positive for tetanus toxoid in 93/139 evaluations, for candida in 41/139 and negative for trichophyton and diphtheria toxin. Conclusions: Children with leukemia experience severe immunological damage after intensive therapy which is gradually improving overtime although some values remain abnormal 6 months after the completion of therapy. It is worth mentioning that despite impaired immune function serious infections were not documented after the first six months of intensive therapy. [Table: see text] No significant financial relationships to disclose.
간세포암종의 혈관신생에서 Angiostatin, Vascular Endothelial Growth Factor, Matrix Metalloproteinase-9 및 12의 역할
Authors: 김숙 ( Kim Sug ), 박호성 ( Park Ho Seong ), 손현진 ( Son Hyeon Jin ), 문우성 ( Mun U Seong )
Journal: Clinical and Molecular Hepatology (2004)

목적: 간세포암종은 혈관 과증식을 특징으로 하는 종양이므로 산소와 영양분을 공급하는 신생혈관의 증식 및 이에 관련된 인자의 발현이 종양의 성장과 전이에 중요한 역할을 할 것으로 생각된다. 대상과 방법: 절제된 48예의 간세포암종을 대상으로 angiostatin, vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMP)-9 및 MMP-12의 발현을 면역조직화학염색으로 연구하고, 이
OP12 UK experience of treatment of chronic viral hepatitis C in children and adolescents: predictors of viral response and quality of life
Authors: M Abdel-Hady, S Bansal, S Davison, M Brown, S Tizzard, S Mulla, P Davies, G Mieli-Vergani, D Kelly
Journal: Gut (2010)

Aim  The aim of this study was to review efficacy, tolerability and quality of life (QoL) in children with chronic hepatitis C (HCV) treated with pegylated interferon (PEG-IFN) alfa2a and ribavirin in 3national specialised referral centres in the UK.  Method  Demographic, laboratory and clinical outcome data on children up to 18 years of age treated for HCV with PEG-IFN alfa2a and ribavirin were reviewed. Information gathered from QoL questionnaires (CHQ-PF28) completed by parents during their children9s treatment was also available for one of the centres. Sustained viral response (SVR) was defined as undetectable HCV RNA at 24 weeks following end of treatment.  Results  The study sample comprised 75 children of whom 38 were males. The median age at the start of the treatment was 10 years (3.0–17.2 years). The most common mode of infection (83%) was via maternal transmission. Thirty-four patients were Genotype 1 (G1); 39 Genotype 2&3 (G2&3); 2 Genotype 4 (G4). SVR was achieved in 47 (73.4%); 53% G 1; 90% G 2&3; 100% G 4. There was no significant difference between baseline ALT and/or AST levels in those who achieved SVR compared to the non-responder group. However the first group had at least 30% lower ALT and /or AST levels at 24 weeks post-treatment compared to the latter group p=0.003 and p=0.001, respectively. Children starting treatment   Conclusion  HCV treatment with PEG-IFN and ribavirin is well tolerated by children with minimal negative impact on the quality of life of a cohort of the studied children and no significant effect on growth. EVR and RVR are good predictors of treatment response.
E2399: Correlation of objective and self report measures of swallowing function after concurrent chemoradiation (CCR) for head and neck cancer (HNC)
Authors: B. A. Murphy, M. S. Dietrich, A. J. Cmelak, B. A. Burtness, A. A. Forastiere
Journal: Journal of Clinical Oncology (2008)

6022 Background: We conducted a correlative study for E2399, a function preservation trial, to assess the acute and long-term effects of CCR on swallowing and the relationship of “gold standard” objective measures to self-report measures. Methods: Swallow evaluations were done at baseline, 3, 12 and 24 months post treatment. Self report measures consisted of the PSS- HN and FACT-G/HN. Objective measures include the modified barium swallow (MBS) scored using a physiologic measure, the Dysphagia Outcome Severity Scale (DOSS) and a functional measure, the Functional Communication Measure (FCM), which is the accepted Medicare standard for assessment of swallow function. Results: Statistically significant correlations were found between the DOSS or FCM and the swallow items for the HN subscale and the PSS-HN. Associations for the FCM were stronger than for the DOSS. At 3-months post-treatment the average correlation of the FCM with the FACT-HN and PSS swallow items was 0.585 (Maximum r =0.746, p < 0.001, Minimum r =0.297, p = 0.074), while the respective average correlation for the DOSS was 0.379 (Maximum r =0.556, p < 0.001, Minimum r =0.078, p = 0.644).There were poor correlations between the DOSS or FCM with the FACT-G at all time points. DOSS scores were lower than FCM scores at all time points (p < 0.05) and the discrepancy between the DOSS and the FCM scores increased post-treatment from an average of 0.43 at 3-months to ∼1.13 at the 24-month assessment. Both the DOSS and the FCM scores at baseline (p < 0.03) and at 3-months (p < 0.01) were associated with overall survival. Conclusions: The DOSS reflects physiologic abnormalities that may not be indicative of clinical dysfunction and therefore demonstrated lower associations with self-report measures of swallowing function than the FCM. The FCM correlated well with the FACT-HN and the PSS-HN swallow items. These findings suggest that PROs have practical utility in assessing swallowing function outcome and may be used in clinical trials as a surrogate for objective measures of swallow function. No significant financial relationships to disclose.
Comparative analysis of CT-scan and PET-scan with intraoperative ultrasound (IOUS) in detecting liver metastases
Authors: M. Patel, S. Saha, R. Sehgal, L. Gallardo, K. Doan, B. Berman, D. Wiese, S. Weiner, M. Arora, T. Singh
Journal: Journal of Clinical Oncology (2006)

3632 Background: Open, laparoscopic or percutaneous radiofrequency ablation (RFA) has been used for the surgical treatment of liver metastases (mets). However, it requires accurate preoperative (preop) localization of liver mets. CT scan and PET scan have been widely used for such preop evaluation. However, intraoperative ultrasound (IOUS) remains the gold standard. Very little data is available comparing IOUS with preop CT and/or PET scan. Thus, a retrospective study was done to compare the efficacy of IOUS with preop CT and/or PET scan in detecting the number of liver mets. Methods: A retrospective chart review was done that included all patients (pts) who underwent surgical treatment for liver mets. Data was obtained from medical records, radiology, intraop reports. Results: 53 pts including 57% men and 43% women with a median age of 62years (age range 35–80 years) were included in the study. Imaging data was available for CT, PET and IOUS in 53, 24 and 39 pts respectively. CT, PET, and IOUS detected 2.4, 1.7 and 2.6 lesions/ pt respectively. In 24 patients, both CT and PET scan report was available. Of these, the imaging study detecting the maximum number of lesions was selected for comparison of preop evaluation with IOUS. A comparison between preop imaging (CT/PET scan) vs. IOUS in these 24 pts revealed an average of 2.3 vs. 2.8 lesions/pt respectively ( Table ). When compared with preop imaging (CT/PET scan), IOUS detected additional lesions in 33% pts; fewer lesions in 17% pts and similar number of lesions in 50% pts. Comparison between CT and IOUS in 39 patients revealed 1.9 vs. 2.6 lesions/pt respectively and that between PET and IOUS in 24 patients revealed 1.7 vs. 2.8 lesions/pt respectively. Conclusions: Although CT scan and PET scan remains effective modalities for preop evaluation of liver mets, IOUS is found to be superior for planning accurate surgical treatment. Thus, the efficacy of percutaneous RFA may be limited due to inability to perform IOUS. [Table: see text] No significant financial relationships to disclose.
Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer
Authors: N. J. Vogelzang, J. B. Nelson, C. C. Schulman, D. P. Dearnaley, F. Saad, D. J. Sleep, J. D. Isaacson, M. A. Carducci
Journal: Journal of Clinical Oncology (2005)

4563 Background: Atrasentan (Xinlay), a selective endothelin-A receptor antagonist, has been studied in 2 randomized placebo controlled studies of men with metastatic hormone-refractory prostate cancer (HRPC) using time to disease progression as the primary endpoint. A meta-analysis of these studies was performed to more precisely define the clinical benefit of atrasentan 10 mg in this patient population. Methods: A meta-analysis using subject-specific data was conducted on the intent-to-treat populations of both studies. Time to disease progression (TTP), time to bone pain (TTBP), as well as time to prostate specific antigen (TTPSA) and bone alkaline phosphatase (TTBALP) progression were analyzed by Kaplan-Meier methodology and by Cox proportional hazards modeling, both stratified by study. Results: 1002 patients were randomized to either atrasentan 10 mg (n=497) or placebo (n=505) in the 2 studies. Atrasentan 10 mg resulted in a statistically significant delay in TTP (log-rank p=0.045), TTBP (log-rank p=0.025), TTPSA (log-rank p=0.002), and TTBALP progression (log-rank p <0.001) compared with placebo. Compared with patients receiving placebo, patients treated with atrasentan 10 mg were 14% less likely to experience disease progression (HR=0.863; 95% CI=0.747, 0.997), had an 18% less likelihood of experiencing bone pain (HR=0.819; 95% CI=0.687, 0.976), had a 22% less chance of experiencing PSA progression (HR=0.775; 95% CI=0.657, 0.914), and were 46% less likely to experience BAP progression (HR=0.537; 95% CI=0.414, 0.695). The relative probability of remaining progression-free was 10% greater at 3 months and 22% greater at 6 months for patients treated with atrasentan 10 mg compared with those treated with placebo, where the probability of remaining progression-free on placebo was 49% and 27% at 3 and 6 months respectively. Conclusions: The results of this analysis demonstrate that atrasentan 10 mg, a novel cytostatic agent, provides significant clinical benefit to patients with metastatic HRPC and indicate that atrasentan would be a valuable addition to the limited treatment options available for these men. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Abbott Laboratories Abbott Laboratories Abbott Laboratories Abbott Laboratories, Aventis, OSI Abbott Laboratories, AstraZeneca, Lilly Oncology, NCI
Primary cardiac angiosarcoma presenting as a malignant pericardial effusion.
Authors: C Wu, M Vasconcelles, P DePiro, A Van den Abbeele, A Rakusin, K Bechard, A Skarin
Journal: Journal of Clinical Oncology (1998)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1998.16.12.3913 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9850037 Primary cardiac angiosarcoma presenting as a malignant pericardial effusion. C WuxC WuSearch for articles by this author , M VasconcellesxM VasconcellesSearch for articles by this author , P DePiroxP DePiroSearch for articles by this author , A Van den AbbeelexA Van den AbbeeleSearch for articles by this author , A RakusinxA RakusinSearch for articles by this author , K BechardxK BechardSearch for articles by this author , A SkarinxA SkarinSearch for articles by this author Show More Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA. https://doi.org/10.1200/JCO.1998.16.12.3913 First Page PDF © 1998 by American Society of Clinical Oncology
Fatigue components in COPD patients and controls using the FACIT-F scale; data from ECLIPSE study
Authors: Khaled Al-Shair, Hana Müllerova, Nicholas Locantore, Nicola Hanania, Amir Sharafkhaneh, Emiel Wouters, Stephen Rennard, Jørgen Vestbo
Journal: European Respiratory Journal (2011)

Introduction:  Fatigue is a complex multi-dimensional phenomenon and its dimensionality in COPD and controls has not been adequately investigated. We aimed to examine the dimensions as well as the reliability and validity of the FACIT-F scale.   Methods:  At baseline, 2107 COPD patients and 576 control subjects with normal lung function from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE; SCO104960, NCT00292552) completed the Functional Assessment of Chronic Illness Therapy (FACIT) fatigue scale. The FACIT-F was readministered to 1621 patients and 515 controls after 3 years. We used the principal components analysis (PCA) for structurally examining the 13 items FACIT-F.   Results:  The 13 items were loaded into two and three interpretable dimensions in COPD and controls, respectively. In COPD, FACIT had high internal consistency (Cronbach9s α= 0.92) and long-term repeatability (r = 0.68, p  FACIT had significant convergent validity; its scores were associated with BODE, SGRQ and MRC dyspnoea scores (r= 0.42, 0.7 and 0.48, respectively, p=   Conclusion:  The FACIT-F is a short and easily administered scale with good validity and reliability in COPD. It may be possible to measure different fatigue components with this scale.
Prognostic role of insulin-like growth factor receptor-1 (IGFR-1) and insulin-like growth factor binding protein-3 (IGFBP-3) expression in small cell lung cancer
Authors: M. Chang, Y. Won, J. Han, H. Kim, O. Kwon, J. Lee, Y. Park, J. Ahn, M. Ahn, K. Park
Journal: Journal of Clinical Oncology (2009)

e22155 Background: Insulin-like growth factor receptor-1 (IGFR-1) is a cellular membrane receptor overexpressed in many tumor cell lines and in some human tumors that seems to play a critical role in anti-apoptosis by enhancing cell survival. Also, insulin-like growth factor binding protein-3 (IGFBP-3) was reported to be a growth suppressor in variable pathways. Purpose of this study was to evaluate the state IGFR-1 and IGFBP-3 expression in patients with small cell lung cancer (SCLC) and its prognostic value. Methods: We analyzed IGFR-1 and IGFBP-3 expression in 194 SCLC tissues specimens by immunohistochemical stain. The relationship between IGFR-1 and IGFBP-3 expression and cliniopathological factors was evaluated. Univariate and multivariate analyses were performed to define its prognostic significance. Results: Median age was 63 years (range 38–85), 84% were men. One hundred-seventeen patients had extensive disease (60.3%), and 77 had limited disease (39.7%). With the median follow- up duration of 49.5 months (24–82), the median progression free survival (PFS) and overall survival (OS) were 8 months (95% CI: 7.3–8.7 months), and 14.4 months (95% CI: 12.7–16 months), respectively, The IGFR-1 expression was observed in 154 of 190 tumor tissues (79.4%), whereas there was no tissue stained by IGFBP-3. Multivariate analysis showed that stage (p&lt;0.001), response to treatment (p&lt;0.001), LDH level (p&lt;0.001) were the independent prognostic factors for PFS, and age (p=0.014), LDH level (p&lt;0.001), and stage (p&lt;0.001) for OS. The IGFR-1 positivity was not associated with PFS or OS in the whole cohort. However, 84% of 115 extensive disease patients showed IGFR-1 positivity. The subgroup analysis revealed that OS was significantly longer for patients with IGFR-1 positive compared to those with IGFR-1 negative in extensive disease (11.3% vs 0% at 2year, p=0.034). Conclusions: These results suggest that IGFR-1 expression may be useful as a prognostic marker in patients with extensive disease of SCLC. No significant financial relationships to disclose.
Phase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC).
Authors: Ann-Lii Cheng, Yoon-Koo Kang, Baek-Yeol Ryoo, Chia-Jui Yen, Ho Yeong Lim, Do-Youn Oh, TaShara Austin, Qiang Wang, Jonathan Greenberg, Robert A. Beckman, Masatoshi Kudo
Journal: Journal of Clinical Oncology (2012)

e14617 Background: Tigatuzumab (T), a humanized monoclonal antibody that acts as a DR5 agonist and exerts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-like activity, is currently undergoing a phase Ib/II study in advanced HCC. Preclinical studies showed that sorafenib (S) can overcome TRAIL resistance in HCC cells and enhances T-induced apoptosis. In this phase Ib dose-escalation portion of a phase 2 study, safety/tolerability of T + S was evaluated in advanced HCC pts. Methods: Adult pts (≥ 18 years) with advanced HCC and measurable disease (RECIST v1.1), ECOG=0/1, and Child-Pugh A, were administered sequentially-escalating doses of T (2, 4, 6 mg/kg/week IV) in combination with S (400 mg PO BID) over 4 weeks (n = 3/cohort). If no pt had a dose-limiting toxicity (DLT), dose escalation proceeded. If 1/3 pts had DLT, the cohort was to be expanded to 6; if 2/3 or 2/6 pts had DLT, the cohort was to be expanded to 9. Dose escalation was to be stopped when ≥ 3 pts experienced DLTs in a cohort with the prior dose designated as the maximum tolerated dose (MTD). Pts received treatment until disease progression, occurrence of unacceptable toxicity, or withdrawal of consent. Results: Nine pts (3 at each dose level of T + S) were treated in this phase Ib portion. Grade 3/4 treatment-emergent AEs (&gt; 20% incidence) were increased AST, blood amylase, and lipase and hand-foot syndrome. Serious AEs were reported in 5 pts (upper GI hemorrhage, esophageal varices hemorrhage [EVH], tumor progression, increased serum amylase, fever, and lumbar spine compression), which were considered unrelated to study medication except for EVH (T + S), increased serum amylase (T + S), and fever (S). No DLTs were observed and the MTD of T was not reached. 2 pts had a partial response, and 4 pts had disease stabilization. The trial is ongoing. Conclusions: Phase Ib data show that T in combination with S was safely administered with no DLT and demonstrated clinical activity in advanced HCC pts. T and S constitute a promising rational combination treatment for HCC.
Prognostic significance of cyclin D1 overexpression in patients (pts) with primary breast cancer (BC)
Authors: M. Ozturk, O. Zekioglu, Y. Erhan, B. C. Bilkay, E. Gokmen
Journal: Journal of Clinical Oncology (2004)

9714 Background: Cyclin D1, a key cell cycle regulator, is overexpressed in approximately 50% of BCs. Previous studies yielded conflicting results on the prognostic importance of cyclin D1 in BC. In this study, we evaluated overexpression of cyclin D1 in primary BC to determine any relation to clinicopathologic factors and its impact on survival. Methods: Formalin fixed tissue samples from 119 pts diagnosed with primary BC in 1996 and 1997 were analyzed for cyclin D1 expression by immunohistochemistry (IHC). A scoring system based on intensity and proportion of staining cells was used to judge cyclin D1 overexpression. ER, PR, Her2-Neu, p53 and Ki-67 expression by IHC and nuclear grade (NG) and histologic grade were determined at the time of diagnosis. OS and DFS curves were estimated by the method of Kaplan-Meier using log rank statistics. Clinicopathologic variables were included in Cox proportional hazards model to determine significance. Results: Cyclin D1 overexpression was observed in 68 of the 119 pts (57%). There was a positive correlation between cyclin D1 overexpression and ER expression (p=0.005) and an inverse correlation between cyclin D1 overexpression and both TNM stage and tumor size (p=0.009 and 0.042). Median follow up was 57 months. In univariate analysis, younger age, nodal involvement and higher NG were associated with poorer DFS (p=0.016, 0.001 and 0.026) and OS (p<0.001, p=0.016 and 0.036). Cyclin D1 had no influence on DFS or OS regardless of the cut point used to define overexpression. Among the ER positive subgroup however, there was a trend for improved OS in pts with cyclin D1 negative tumors (p=0.08). In contrast, cyclin D1 expression did not influence OS in ER negative subset. When ER positive pts with ductal carcinoma histology were considered, cyclin D1 negativity was associated with a better prognosis (p=0.053). In multivariate analyses of DFS and OS, only the nodal status (p=0.031 and 0.023) and NG (p=0.029 and 0.039) remained statistically significant. Conclusions: Cyclin D1 overexpression is not an independent predictor of prognosis in BC. In ER positive subgroup however, there is a trend for improved survival in cyclin D1 negative pts. No significant financial relationships to disclose.
Statement of Retraction. Nuts as a Replacement for Carbohydrates in the Diabetic Diet. Diabetes Care 2011;34:1706–1711. DOI: 10.2337/dc11-0338
Authors: David J.A. Jenkins, Cyril W.C. Kendall, Monica S. Banach, Korbua Srichaikul, Edward Vidgen, Sandy Mitchell, Tina Parker, Stephanie Nishi, Balachandran Bashyam, Russell de Souza, Christopher Ireland, Robert G. Josse
Journal: Diabetes Care (2016)

The authors wish to retract this article because of an unintended error in statistical applications. A subsequent reanalysis of the data has shown that a number of the findings of the study described in this publication are no longer definitively different. The corresponding author voluntarily reported these discrepancies to the editors of Diabetes Care. The decision to retract the article is supported by all the authors based on their reevaluation of the data. The decision to retract the article is also supported by the editors of the journal and the American Diabetes Association, the publisher of Diabetes Care. At a later date, the authors intend to submit a revised article to Diabetes Care for full peer review with the appropriate statistical analysis applied.
Serum Haptoglobin Type and Leukemia: An Association With Possible Etiological Significance
Authors: Andrew C. Peacock
Journal: JNCI Journal of the National Cancer Institute (1966)

Haptoglobin type has been determined in 79 subjects with leukemia of various types, and the distributions observed compared with normal populations. The leukemic population contained an excess of individuals homozygous for haptoglobin type 1–1 and a deficiency of individuals homozygous for haptoglobin type 2–2. Data from similar clinical studies and a comparison of the incidence of haptoglobin genes and leukemia mortality suggest that the gene for haptoglobin protein type 2 confers resistance to leukemia on the holder to such an extent that the relative risk of leukemia among homozygous 1–1 as compared with subjects 2–2 is approximately fourfold. The observed dirferences in susceptibility may be related to the chemical action of haptoglobin on some leukemogenic agent.